Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ� (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management.
That being the case, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) seems to have come to the realization that unless it takes proactive steps to expand the market share of its anti-obesity drug Belviq, it might as well miss out on a great opportunity.
Dallas, Texas 04/17/2014 (ustradevoice) - One of the main reasons, analysts and pundits say, why Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has not had success with its FDA-approved weight management drug known as Belviq, is lack of awareness.
Free technical research on ARNA, CELG, PDLI and HEB can be downloaded upon signing up at: http://www.investor-edge.com/905-register On Monday, shares in Arena Pharmaceuticals Inc. gained 2.57% to close the day at $6.38. The stock recorded a ...
It is certainly an interesting time to be an investor in Arena Pharmaceuticals (ARNA). The company is about 10 months into its launch of the anti-obesity drug Belviq and the equity has taken several lumps along the way.